IN8bio logo

IN8bioNASDAQ: INAB

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

30 July 2021

Next earnings report:

14 March 2025

Last dividends:

N/A

Next dividends:

N/A
$25.12 M
-83%vs. 3y high
27%vs. sector
-vs. 3y high
-vs. sector
-49%vs. 3y high
70%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Fri, 15 Nov 2024 22:58:12 GMT
$0.35+$0.02(+5.83%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

INAB Latest News

IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
globenewswire.com12 November 2024 Sentiment: POSITIVE

Reported 100% of Acute Myeloid Leukemia (AML) patients treated in INB-100 remain in complete remission (CR) at the 2024 European Hematology Association Congress and received FDA guidance for a future INB-100 registrational trial INB-100 trial currently expanding enrollment up to approximately 25 patients at the recommended Phase 2 dose (RP2D) along with the potential to add additional centers and a prospective parallel observational cohort as a control Closed private placement for net proceeds of $11.6 Million in October 2024 extending cash runway through 2025 NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) --   IN8bio, Inc . (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer, today reported financial results for the third quarter ended September 30, 2024, and recent corporate highlights.

IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100
globenewswire.com12 August 2024 Sentiment: POSITIVE

Received FDA guidance on the registrational path for INB-100 in acute myeloid leukemia (AML), an investigational allogeneic gamma-delta T cell therapy, with IND submission anticipated in Q1 2025. Early clinical data from investigator sponsored trials demonstrates prolonged relapse-free survival across both AML and glioblastoma (GBM) programs, compared to current standard-of-care, with both programs advancing to Phase 2 clinical development.

IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
globenewswire.com24 June 2024 Sentiment: POSITIVE

NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that William Ho, CEO and Co-founder, will participate in a fireside chat during the H.C. Wainwright 2 nd Annual Immune Cell Engager Virtual Conference on Tuesday, June 25, 2024 at 2:30 p.m. ET.

IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100
globenewswire.com13 June 2024 Sentiment: POSITIVE

100% of treated leukemia patients (n=10/10) achieved durable complete remission (CR) at 1-year, including high-risk and relapsed acute myeloid leukemia (AML) patients who had previously failed multiple lines of therapy, including CAR-T. Data continue to show long-term in vivo expansion and persistence of allogeneic gamma-delta T cells 365 days following a single administration, demonstrating first-ever durable persistence and expansion of an allogeneic cellular therapy.

IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting
globenewswire.com03 June 2024 Sentiment: POSITIVE

92% of evaluable patients treated with INB-200 for glioblastoma exceeded a median progression-free survival (PFS) of seven months achieved with the standard-of-care regimen (Stupp regimen) Majority of fully dosed patients exceeded the expected median PFS based on age and tumor status; one patient from Cohort 2 remains alive and progression free at almost three years Radiologic evaluation indicative of “treatment effect” including changes in MRI enhancement and resolution of mid-line shift NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies, presented encouraging preliminary clinical data of INB-200 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on June 1, 2024. The preliminary data demonstrated that 92% of evaluable patients treated with INB-200 exceeded a median PFS of 7 months (median follow-up: 11.7 months) with concomitant temozolomide (TMZ), as of a data cutoff date of May 30, 2024.

IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024
globenewswire.com24 May 2024 Sentiment: POSITIVE

NEW YORK, May 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced multiple presentations at the International Society for Cell & Gene Therapy 2024, to be held May 28th to June 1st in Vancouver, Canada. “ISCT is a scientific gathering renowned for fostering groundbreaking ideas and innovation in cellular therapies,” said Dr. Kate Rochlin, Chief Operating Officer of IN8bio.

IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting
globenewswire.com23 May 2024 Sentiment: POSITIVE

NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an upcoming presentation of updated results from its fully enrolled Phase 1 study of INB-200 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 31st - June 4th in Chicago, Illinois. INB-200 is evaluating autologous Drug Resistant Immunotherapy (DeltEx DRI) or chemotherapy resistant gamma-delta T cells as a potential first-line treatment for patients with newly diagnosed glioblastoma multiforme (GBM).

IN8bio to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology (ASH) Annual Meeting
GlobeNewsWire02 November 2023 Sentiment: POSITIVE

NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an abstract detailing new, positive data from the Phase 1 investigator-sponsored trial of INB-100 in patients with hematologic malignancies has been selected for poster presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 9-12, 2023.

IN8bio, Inc. (INAB)'s Technical Outlook is Bright After Key Golden Cross
Zacks Investment Research05 June 2023 Sentiment: POSITIVE

IN8bio, Inc. (INAB) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, INAB's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.

IN8bio, Inc. (INAB) Is Up 37.87% in One Week: What You Should Know
Zacks Investment Research24 May 2023 Sentiment: POSITIVE

Does IN8bio, Inc. (INAB) have what it takes to be a top stock pick for momentum investors? Let's find out.

What type of business is IN8bio?

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of solid and liquid tumors. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM and other cancers; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company develops INB-300 and INB-500 that are in preclinical phase for treatment of acute myeloid leukemia, and other solid and hematological tumor types. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is based in New York, New York.

What sector is IN8bio in?

IN8bio is in the Healthcare sector

What industry is IN8bio in?

IN8bio is in the Biotechnology industry

What country is IN8bio from?

IN8bio is headquartered in United States

When did IN8bio go public?

IN8bio initial public offering (IPO) was on 30 July 2021

What is IN8bio website?

https://in8bio.com

Is IN8bio in the S&P 500?

No, IN8bio is not included in the S&P 500 index

Is IN8bio in the NASDAQ 100?

No, IN8bio is not included in the NASDAQ 100 index

Is IN8bio in the Dow Jones?

No, IN8bio is not included in the Dow Jones index

When was IN8bio the previous earnings report?

No data

When does IN8bio earnings report?

The next expected earnings date for IN8bio is 14 March 2025